

Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 17th April 2024 10-11:30am

Microsoft Teams Meeting

Present:	Mehrdad Malekian (MM) (Chair) Victoria Gemmell (VG) (Minutes) Tyra Smyth (TS) Mark Kirk (MK) Kelly Baillie (KB) Gail Richardson (GR) Alistair Brown (AB)	Kendal Paterson (KP)(observer) Lorna Templeton(LT) (item 8a) Michael Cooper (MC) (Item 8b) David Semple (DS) Linda Johnstone (LJ) Christine Gilmour (CG) Penny Brankin (PB)
1. Apologies:	Colin Angus	Chris Miller
2. Declaration of Interest	nil	

--	--	--

Item	Notes	Action
3.	<u>Minutes/Actions from the last meeting</u> The minutes were accepted as true records and can now be published	VG
4.	<u>Matters Arising</u>	
a.	Off-Label Prescribing-Use of Medicines Outside of their UK Marketing Authorisation in Palliative Medicine-Prescribing for Off-Label Indications or Unlicensed Medicines This is the palliative care section to go alongside the new UL medicines policy. It was approved and can be shared as soon as the main Unlicensed Medicines Policy is ratified.	
b.	SGLT2i for Treatment of Chronic Kidney Disease SGLT2i CKD NHSL Guideline Update awaited	
c.	Ryeqo Update awaited	
d.	Wegovy® (Semaglutide) for Weight Management This was shared with both Acute and Primary Care PMMB's The guideline for the medicine has been approved by ADTC, and it will now proceed through standard procedures for evaluation and consideration of cost and service implications.	
e.	NIV Withdrawal Guideline Update awaited	
f.	Progesterone in Pregnancy Guideline GR gave an update. This has been approved. Further details around supply will be formalised via maternity at UHW.	

	<p>g. GLP-1 Guideline The additions were accepted by the group. This was approved and can be shared.</p> <p>h. Finerenone Diabetic Kidney Disease Update awaited</p> <p>i. Avacopan for ANCA Vasculitis Update awaited</p> <p>j. SAPG Response to MHRA updated statement on use of fluoroquinolones Update awaited</p>	
5.	<p>SMC Advice-CONFIDENTIAL Please all see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website after 10.00 am on Monday 13 May 2024.</p> <p>Full Submissions</p> <ul style="list-style-type: none"> • ruxolitinib topical (Opzelura) Incyte Biosciences UK Ltd SMC2634 for the treatment of non-segmental vitiligo (NSV) with facial involvement in adults and adolescents from 12 years of age. Not Recommended. FOR NOTING • budesonide/formoterol (Symbicort Turbohaler) AstraZeneca UK Ltd SMC2622 As reliever therapy for adults and adolescents (12 years and older) with mild asthma. Accepted Restricted. REFER TO RESPIRATORY <p>Non Submission</p> <ul style="list-style-type: none"> • zanubrutinib (Brukinsa) BeiGene UK Ltd SMC2671 Not Recommended DUE TO NON SUBMISSION <p>Amended Advice-FOR NOTING <u>tirzepatide solution for injection in pre-filled pen (Mounjaro®) Eli Lilly and Company Limited SMC2633</u> Minor amendments have been made to the Detailed Advice Document (DAD) for tirzepatide (Mounjaro®), for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:</p> <ul style="list-style-type: none"> • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. <p>The DAD will be reissued to Boards on Friday 05 April 2024 and published on the website on Monday 08 April 2024.</p> <p>Ultra Orphan For NOTING The following medicine did not meet the revised UO definition:</p> <ul style="list-style-type: none"> • tofesen sodium (Qalsody®) for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. <p>Boards are reminded that any request to access treatment with a validated ultra-orphan prior to its availability within the ultra-orphan pathway should be considered through local non-formulary processes.</p>	
6.	<p>SMC follow up Migraine treatment advice remains awaited</p>	

	Empagliflozin and dapagliflozin-annotate as <i>Not routinely available as there is a local preference for alternative medicines</i> as we have not received any further communication since feedback was given post November meeting	
7.	<p><u>Lanarkshire Formulary</u></p> <p>Formulary Amendment-Eylea. Proposal to move to 8mg strength. The Committee noted this request - it will proceed through standard procedures for evaluation of cost and service implications.</p> <p>Formulary Amendment-Safety needles. This was agreed.</p> <p>Medicines Guidance Formulary Paper-This was agreed.</p> <p>Draft Formulary Amendment Form-This was agreed with no further changes and can be implemented.</p>	
8.	<p><u>Clinical Protocols</u></p> <p>a. Delirium Guideline MC gave a summary of the guidance. The committee felt this was a helpful update to the previous document. A point was raised regarding post-discharge follow up. It was agreed to amend the wording slightly and return for final review. Latin abbreviations to be amended.</p> <p>b. Valproate RAF Process Update LT gave a summary on the need for formal processes in MH & LD to ensure the service is meeting regulatory changes required by the MHRA regarding prescribing of medicines containing valproate. It was agreed the document provided helpful advice which was appreciated. A comment regarding using alternative means of communication with patients who DNA was noted, as well as clarification of the abbreviation DMP (for Designated Medical Practitioner- a term for 2nd opinion doctors for patients detained under MHA legislation). The document was approved pending these changes. LT can upload to CG website once changes are actioned.</p>	
9.	<p><u>ADTC New Medicines Decisions</u></p> <p>Includes an update to previous COVID medicines decisions, including the withdrawal of MA for Casirivimab and imdevimab (Ronapreve) This was approved and can be published.</p>	
10.	<p><u>Unlicensed Medicines</u></p> <p>a. GR gave an update of progress of the development of the new Unlicensed Medicines policy. Elements include</p> <ul style="list-style-type: none"> • QR codes for consent forms • A centrally held database <p>Policy to be presented to MH D and T and also PMMB for comment A communication strategy will also be developed.</p>	

11.	<u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update NIL	
12.	<u>Regional Cancer Advisory Network</u> Kelly Baillie gave a summary to the group. The recommendations were accepted.	
13.	<u>Patient Safety Alerts</u> NIL	
14.	<u>Lay member related items</u> NIL	
15.	<u>Correspondence</u> a. <u>ADTC Collaborative (ADTCC Forum-any updates post meeting. Prof Sec attends)</u> i. <u>ADTCC March Newsletter</u> This was noted	
16.	<u>Pharmacy & NMAHP Prescribing Governance</u> NIL	
17.	<u>AOCB</u> a. GR informed the group of concerns around pending shortage of IV Pabrinex and planned discontinuation of IM Pabrinex. Acute services are working with NP and other Boards to source sustainable alternatives. There are two formulary entries for Pabrinex	
18.	<u>Date of next meeting</u> Wednesday 15th May 2024 10-11:30am MS TEAMS	